Outcomes and patterns of treatment in chronic myeloid leukemia, a global perspective based on a real-world data global network
Blood Cancer J
.
2022 Jun 24;12(6):94.
doi: 10.1038/s41408-022-00692-8.
Authors
A Sanz
#
1
,
R Ayala
#
1
,
G Hernández
2
,
N Lopez
1
,
D Gil-Alos
1
,
R Gil
1
,
R Colmenares
1
,
G Carreño-Tarragona
1
,
J Sánchez-Pina
1
,
R A Alonso
1
,
N García-Barrio
3
,
D Pérez-Rey
2
,
L Meloni
4
,
M Calbacho
1
,
J Cruz-Rojo
3
,
M Pedrera-Jiménez
3
,
P Serrano-Balazote
3
,
J de la Cruz
5
,
J Martínez-López
6
Affiliations
1
Hematology Department, Hospital 12 de Octubre, Complutense University, CNIO, Madrid, Spain.
2
Biomedical Informatics Group, Universidad Politécnica de Madrid, Madrid, Spain.
3
Data Science Group, Research Institute imas12, Hospital 12 de Octubre, Madrid, Spain.
4
TriNetX, LLC, Cambridge, MA, USA.
5
Research Institute imas12, Hospital 12 de Octubre, Madrid, Spain.
6
Hematology Department, Hospital 12 de Octubre, Complutense University, CNIO, Madrid, Spain. jmartinezlo1967@gmail.com.
#
Contributed equally.
PMID:
35750670
PMCID:
PMC9232604
DOI:
10.1038/s41408-022-00692-8
No abstract available
MeSH terms
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / epidemiology
Leukemia, Myeloid*
Substances
Imatinib Mesylate